SAN DIEGO, Sept. 6, 2011 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the
Company's Chief Executive Officer, Brian M.
Culley, will present at the Rodman & Renshaw Annual
Global Investment Conference on Monday
September 12, 2011 at 2:25 p.m.
Eastern time, in the Metropolitan East Salon at the
Waldorf=Astoria Hotel in New
York.
Interested parties can access a live audio webcast and slide
presentation on the ADVENTRX Pharmaceuticals web site at
www.adventrx.com. An archived presentation will be available on the
web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company
focused on developing proprietary product candidates. The
Company's current lead product candidates are ANX-188, a novel,
purified, rheologic and antithrombotic compound initially being
developed as a first-in-class treatment for pediatric patients with
sickle cell disease in acute crisis, and ANX-514, a detergent-free
reformulation of the blockbuster drug Taxotere®, which recently
went off-patent. The Company is evaluating its Exelbine
program following the complete response letter it received from the
FDA. More information can be found on the Company's web site
at www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals